PSMA配体PET/CT与多参数MRI检测盆腔复发性前列腺癌的比较
该回顾性研究比较了68Ga-PSMA-11 PET/CT与盆腔MRI对复发性前列腺癌的检测效能,43例患者中PSMA-PET/CT检出38例(88.4%)阳性,MRI检出30例(69.8%)阳性;PSMA-PET/CT检出75个盆腔病灶,MRI检出53个(其中13个不确定),仅在将不确定病灶归为假阳性时PSMA-PET/CT的优越性才具有统计学意义。
要点
- PSMA-PET/CT检出盆腔复发病灶数多于MRI(75 vs 53)。
- PSMA-PET/CT阳性患者比例高于MRI(88.4% vs 69.8%)。
- PSMA-PET/CT的统计学优越性仅在不明确病灶视为假阳性时成立。
核心结论
- 与MRI相比,PSMA-PET/CT检测到更多盆腔复发性前列腺癌特征性病灶。
- 未来可考虑先行PSMA-PET/CT检测复发,PET/MRI混合扫描可结合两者优势。
研究设计与样本
- 回顾性分析2017年1月至2018年9月在本机构行全身68Ga-PSMA-11 PET/CT检测复发性前列腺癌的患者,其中43例在2个月内额外接受盆腔MRI。
- PET数据由两名核医学医师共识判读,MRI由两名放射科医师判读,记录病灶类型和位置后逐患者、逐病灶直接比较。
主要发现
- 43例中30例(69.8%)MRI显示盆腔病理性表现,38例(88.4%)PSMA-PET/CT显示盆腔病理性表现。
- MRI检出53个盆腔复发性前列腺癌病灶(13个分类为「不确定」),PSMA-PET/CT检出75个盆腔病灶(3个分类为「不确定」)。
- 仅当不确定病灶被归类为假阳性时,PSMA-PET/CT的优越性才具有统计学意义。
临床怎么用
- 检测复发性前列腺癌时可考虑先行PSMA-PET/CT。
- PET/MRI混合扫描可结合PSMA-PET/CT与MRI的优势。
局限性
- 回顾性分析,样本量43例。
- 仅纳入2个月内额外接受盆腔MRI的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: So far, there have been very few studies which provide a direct comparison between MRI and PSMA-ligand PET/CT for the detection of recurrent prostate cancer (rPC). This present study therefore aims to provide further clinical data in order to resolve this urgent clinical question, and thereby strengthen clinical recommendations. METHODS: A retrospective analysis was performed for patients who were scanned at our institution with whole-body PSMA-PET/CT (tracer: 68Ga-PSMA-11) between January 2017 and September 2018 in order to detect rPC. Amongst them, 43 underwent an additional pelvic MRI within 2 months. Both modalities were compared as follows: a consensus read of the PET data was performed by two nuclear physicians. All lesions were recorded with respect to their type and localization. The same process was conducted by two radiologists for pelvic MRI. Thereafter, both modalities were directly compared for every patient and lesion. RESULTS: Overall, 30/43 patients (69.8%) presented with a pathologic MRI and 38/43 (88.4%) with a pathologic PSMA-PET/CT of the pelvis. MRI detected 53 pelvic rPC lesions (13 of them classified as "uncertain") and PSMA-PET/CT detected 75 pelvic lesions (three classified as "uncertain"). The superiority of PSMA-PET/CT was statistically significant only if uncertain lesions were classified as false-positive. CONCLUSIONS: PSMA-PET/CT detected more pelvic lesions characteristic for rPC when compared to MRI. In order to detect rPC, a potential future scenario could be conducting first a PSMA-PET/CT. Combining the advantages of both modalities in hybrid PET/MRI scanners would be an ideal future scenario.
引用
- Afshar-Oromieh A, Vollnberg B, Alberts I, et al. Comparison of PSMA-ligand PET/CT and multiparametric MRI for the detection of recurrent prostate cancer in the pelvis. Eur J Nucl Med Mol Imaging. 2019. PMID: 31350604. doi:10.1007/s00259-019-04438-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。